Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedNov 06, 2025
DataAggregated Company Financials
Companies4
  • 7D-0.9%
  • 3M-0.7%
  • 1Y-1.6%
  • YTD17.5%

The Biotech industry is up 2.7% in the last week, with Molecular Partners up 16%. Overall in the last year, the industry is flat. Earnings are forecast to grow by 35% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 06 Nov 2025CHF 1.8bCHF 343.6m-CHF 10,514,000.007.7x-175.8x5.4x
Sat, 04 Oct 2025CHF 1.9bCHF 344.3m-CHF 15,083,000.008.2x-123.2x5.4x
Mon, 01 Sep 2025CHF 1.8bCHF 383.4m-CHF 57,057,000.008x-32.4x4.8x
Wed, 30 Jul 2025CHF 2.2bCHF 333.9m-CHF 44,705,000.009.2x-49.1x6.6x
Fri, 27 Jun 2025CHF 2.0bCHF 333.9m-CHF 44,705,000.007.6x-44x5.9x
Sun, 25 May 2025CHF 1.8bCHF 333.9m-CHF 44,705,000.007x-40.2x5.4x
Tue, 22 Apr 2025CHF 1.6bCHF 411.1mCHF 65.6m4.7x24.8x4x
Thu, 20 Mar 2025CHF 1.7bCHF 409.3m-CHF 35,110,868.005.3x-48x4.1x
Sat, 15 Feb 2025CHF 2.0bCHF 327.8m-CHF 127,073,868.003.3x-15.4x6x
Mon, 13 Jan 2025CHF 1.9bCHF 330.3m-CHF 75,131,868.002.7x-24.6x5.6x
Wed, 11 Dec 2024CHF 1.6bCHF 330.9m-CHF 87,805,465.001.7x-18.5x4.9x
Fri, 08 Nov 2024CHF 2.0bCHF 331.2m-CHF 86,988,629.001.7x-22.6x5.9x
Sun, 06 Oct 2024CHF 1.5bCHF 333.1m-CHF 82,023,629.001.7x-18.7x4.6x
Tue, 03 Sep 2024CHF 1.5bCHF 323.4m-CHF 89,161,264.002x-16.8x4.6x
Thu, 01 Aug 2024CHF 799.5mCHF 151.7m-CHF 146,197,264.001.6x-5.5x5.3x
Sat, 29 Jun 2024CHF 755.7mCHF 151.7m-CHF 146,197,264.001.4x-5.2x5x
Mon, 27 May 2024CHF 542.4mCHF 170.5m-CHF 131,456,924.261x-4.1x3.2x
Wed, 24 Apr 2024CHF 412.4mCHF 67.2m-CHF 172,323,373.380.09x-2.4x6.1x
Fri, 22 Mar 2024CHF 335.2mCHF 67.3m-CHF 173,226,268.680.2x-1.9x5x
Sun, 18 Feb 2024CHF 398.9mCHF 55.5m-CHF 173,229,467.361x-2.3x7.2x
Tue, 16 Jan 2024CHF 344.1mCHF 317.5m-CHF 176,052,810.000.5x-2x1.1x
Thu, 14 Dec 2023CHF 302.4mCHF 317.9m-CHF 209,013,230.00n/a-1.4x1x
Sat, 11 Nov 2023CHF 292.3mCHF 318.5m-CHF 211,316,499.00n/a-1.4x0.9x
Mon, 09 Oct 2023CHF 258.0mCHF 318.5m-CHF 213,382,358.00n/a-1.2x0.8x
Wed, 06 Sep 2023CHF 323.7mCHF 318.6m-CHF 188,826,658.00n/a-1.7x1x
Fri, 04 Aug 2023CHF 538.7mCHF 324.3m-CHF 180,121,509.00n/a-3x1.7x
Sun, 02 Jul 2023CHF 302.2mCHF 330.6m-CHF 180,777,833.00n/a-1.7x0.9x
Tue, 30 May 2023CHF 326.8mCHF 332.8m-CHF 183,369,210.00n/a-1.8x1x
Thu, 27 Apr 2023CHF 436.5mCHF 498.0m-CHF 18,428,774.001.6x-23.7x0.9x
Sat, 25 Mar 2023CHF 426.5mCHF 497.1mCHF 11.5m1.5x37x0.9x
Mon, 20 Feb 2023CHF 480.8mCHF 493.4mCHF 14.5m1.6x33.2x1x
Wed, 18 Jan 2023CHF 527.8mCHF 493.4mCHF 14.5m1.8x36.4x1.1x
Fri, 16 Dec 2022CHF 492.8mCHF 493.4mCHF 14.5m1.7x34x1x
Sun, 13 Nov 2022CHF 524.8mCHF 493.6mCHF 15.0m1.8x35x1.1x
Price to Earnings Ratio

35x


Total Market Cap: CHF 524.8mTotal Earnings: CHF 15.0mTotal Revenue: CHF 493.6mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average -11.4x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 5.5x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 11% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.051%
Healthcare1.47%
Biotech-0.90%
Biotech-0.90%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MOLN Molecular PartnersCHF 3.4416.4%
+CHF 18.2m		-38.0%PB1.3x
SANN Santhera Pharmaceuticals HoldingCHF 10.503.6%
+CHF 4.8m		20.8%PS2.9x

Latest News

IDIA
CHF 3.29
Idorsia
7D
-2.5%
1Y
256.6%

IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift

Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.
KURN
CHF 28.70
Kuros Biosciences
7D
-2.2%
1Y
4.4%

Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts

Oct 18
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
SANN
CHF 10.50
Santhera Pharmaceuticals Holding
7D
3.6%
1Y
20.8%
BSLN
CHF 45.55
Basilea Pharmaceutica
7D
-1.2%
1Y
6.9%
MOLN
CHF 3.44
Molecular Partners
7D
16.4%
1Y
-38.0%
RLF
CHF 2.93
Relief Therapeutics Holding
7D
-7.9%
1Y
-48.6%